l e t t e r s
We conducted a genome-wide association study of pancreatic cancer in 3,851 affected individuals (cases) and 3,934 unaffected controls drawn from 12 prospective cohort studies and 8 case-control studies. Based on a logistic regression model for genotype trend effect that was adjusted for study, age, sex, self-described ancestry and five principal components, we identified eight SNPs that map to three loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Two correlated SNPs, rs9543325 (P = 3.27 × 10 −11 , per-allele odds ratio (OR) 1.26, 95% CI 1.18-1.35) and rs9564966 (P = 5.86 × 10 −8 , per-allele OR 1.21, 95% CI 1.13-1.30), map to a nongenic region on chromosome 13q22.1. Five SNPs on 1q32.1 map to NR5A2, and the strongest signal was at rs3790844 (P = 2.45 × 10 −10 , per-allele OR 0.77, 95% CI 0.71-0.84). A single SNP, rs401681 (P = 3.66 × 10 −7 , per-allele OR 1.19, 95% CI 1.11-1.27), maps to the CLPTM1L-TERT locus on 5p15.33, which is associated with multiple cancers. Our study has identified common susceptibility loci for pancreatic cancer that warrant follow-up studies.
Pancreatic cancer is one of the most lethal cancers, with mortality rates approaching its incidence rates 1 . Established risk factors for pancreatic cancer include diabetes, an elevated body-mass index, current or recent smoking and family history of pancreatic cancer 2 . However, only a small fraction of familial aggregation of pancreatic cancer can be explained by previously identified, highly penetrant mutations in BRCA2, CDKN2A (also known as p16), STK11 (also known as LKB), APC, BRCA1, PRSS1 and SPINK 2, 3 . Truncating mutations and deletions in PALB2 have also recently been shown to be involved in familial pancreatic cancer 4, 5 .
We recently reported common risk variants for pancreatic cancer that map to the first intron of the ABO gene on chromosome 9q34.2 based on a genome-wide association study (GWAS) of 1,896 individuals diagnosed with pancreatic cancer and 1,939 controls 6 . Individuals were drawn from 12 prospective cohort studies (from the Pancreatic Cancer Cohort Consortium) and 1 hospital-based case-control study, the Mayo Clinic Molecular Epidemiology of Pancreatic Cancer Study (Online Methods) 6 . In the first scan, we genotyped approximately 550,000 SNPs and followed up the most significant SNPs that had been found in eight case-control studies (Online Methods) 6 .
To identify additional loci, we conducted a second GWAS in which we genotyped approximately 620,000 SNPs in an additional 1,955 cases and 1,995 controls drawn from the same eight case-control studies used to replicate the initial GWAS finding on chromosome 9q34.2. After quality control analysis of genotypes, we combined the datasets, resulting in 551,766 SNPs available for analysis (using Illumina A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33 l e t t e r s HumanHap550 and Human 610-Quad chips) in 3,851 individuals with pancreatic cancer and 3,934 controls (Online Methods). A logistic regression model was fit for genotype trend effects (1 degree of freedom (d.f.)) adjusted for study, age, sex, self-described ancestry and five principal components of population stratification. The quantilequantile plot showed little evidence for inflation of the test statistics as compared to the expected distribution (λ = 1.013), which excludes the likelihood of substantial hidden population substructure or differential genotype calling between cases and controls ( Supplementary  Fig. 1) . A Manhattan plot displays the results of the combined GWAS (Supplementary Fig. 2a ) and the results from the case-control studies including the full Mayo dataset (Supplementary Fig. 2b ). Our combined analysis identified three new genomic regions on chromosomes 13q22.1, 1q32.1 and 5p15.33 associated with pancreatic cancer risk that were below the threshold for genome-wide significance (P < 5 × 10 −7 ), as shown in Table 1 and Figure 1 (ref. 7) . Two different haplotype analyses that involve different test statistics were conducted for each of the three regions: a regularized regression 8 and a sequential haplotype scan 9 (Online Methods). Haplotype analysis across each of the three regions did not identify new or independent markers, thus indicating that the current tag SNPs probably implicate single loci in each region (Supplementary Fig. 3 ).
For the locus on 13q22.1, we observed two highly significant SNPs that ranked number 1 and 6 (most significant and sixth most significant) in the combined analysis: rs9543325 (P = 3.27 × 10 −11 , per-allele OR 1.48 , 95% CI 1.27-1.72). These SNPs, which are 20 kb apart, are highly correlated (r 2 = 0.82 in 3,650 study controls of European ancestry and r 2 = 0.85 in the HapMap CEU population). SNP rs9564966 was no longer nominally significant after adjusting for rs9543325 (P = 0.47), suggesting that the two SNPs mark a single signal in the approximately 600-kb nongenic region between two genes in the family of kruppel-like transcription factors, KLF5 and KLF12, that regulate cell growth and transformation 10, 11 . This segment of chromosome 13 is frequently deleted in a spectrum of cancers, including pancreatic cancer 12, 13 , and may harbor a breast cancer susceptibility locus, as indicated by linkage analysis in families with breast cancer that are negative for mutations in BRCA1 and BRCA2 genes 14 . The results from the unconditional logistic regression of the genotypes generated in a total of 3,851 individuals with pancreatic cancer and 3,934 controls. The analysis was adjusted for age in 10-year categories, sex, study, arm, ancestry and five principal components of population stratification. The SNPs on chromosome 13q22.1 are within a 600-kb intergenic region between KLF5 and KLF12. 
Five highly significant SNPs (ranked 2, 3, 4, 7 and 9 in significance in the combined analysis; P ≤ 5 × 10 −7 ) map to a region of chromosome 1q32.1 that harbors NR5A2 (encoding nuclear receptor subfamily 5, group A, member 2). The SNPs are distributed across a 105-kb genomic region that includes the 5′ end of NR5A2 and extends to 91 kb upstream of the gene. The two most significant SNPs in this region map to the first intron of NR5A2 (rs3790844, P = 2.45 × 10 −10 , per-allele OR 0.77, 95% CI 0.71-0.84; unconstrained OR het 0.75, 95% CI 0.68-0.83 and unconstrained OR hom 0.64, 95% CI 0.52-0.79) and are approximately 32 kb upstream of the gene (rs10919791, P = 6.37 × 10 −10 ; per allele OR 0.77, 95% CI 0.71-0.84; unconstrained OR het 0.76, 95% CI 0.68-0.84 and unconstrained OR hom 0.63, 95% CI 0.50-0.79). The linkage disequilibrium (LD) between these two SNPs is high, with r 2 = 0.81 in study controls and r 2 = 0.71 in the HapMap CEU. In this region, there were three additional SNPs, rs3790843, rs12029406 and rs4465241, that were highly significant (P < 5 × 10 −7 ). Of these three SNPs, the most telomeric one, rs3790843, is highly correlated with rs3790844 and rs10919791 (r 2 = 0.59 and 0.72 in Pancreatic Cancer Cohort Consortium (PanScan) European controls). The two SNPs centromeric to rs3790844 and rs10919791 are less strongly correlated (r 2 = 0.05-0.38 in PanScan European controls). In an analysis adjusted for the most highly associated SNP, rs3790844, three of the other four SNPs, rs10919791, rs3790843 and rs12029406, were no longer nominally significant (P > 0.05), whereas the significance of the association with rs4465241 (which had the lowest LD) decreased by several orders of magnitude after adjustment (P = 0.004). Together, these findings suggest that these five SNPs mark a single common allele, but further fine-mapping will be needed to confirm this.
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The third locus identified is marked by rs401681 (P = 3.66 × 10 −7 , per-allele OR 1.19, 95% CI 1.11-1.27; unconstrained OR het 1.20, 95% CI 1.07-1.34 and unconstrained OR hom 1.41, 95% CI 1.23-1.61), which maps to chromosome 5p15.33. It resides in intron 13 of CLPTM1L (encoding cleft lip and palate transmembrane 1-like), which is part of the CLPTM1L-TERT locus that includes TERT (encoding telomerase reverse transcriptase), which is only 23 kb away from CLPTM1L. Both genes have been implicated in carcinogenesis: CLPTM1L is upregulated in cisplatin-resistant cell lines and may play a role in apopotosis 18 , whereas TERT encodes the catalytic subunit of telomerase, which is essential for maintaining telomere ends. When overexpressed in normal cells, TERT can lead to prolonged cell lifespan and transformation 19, 20 . Although telomerase activity cannot be detected in most normal tissues, it is seen in approximately 90% of human cancers 21 . This region of chromosome 5p15.33 has been identified in GWAS of a number of different cancers, including brain tumors, lung cancer, basal cell carcinoma, melanoma and now pancreatic cancer [22] [23] [24] [25] [26] . In a recent analysis of lung cancer in smokers, the signal on chromosome 5p15.33 has been shown to be strongly associated with the adenocarcinoma histology subtype 27 . Moreover, another variant in this region, rs402710, that is in LD with our strongest signal, rs401681, has been suggested to be associated with levels of smokingrelated bulky aromatic DNA adducts; this is relevant for pancreatic cancer because this cancer is also associated with tobacco use 28 . Germline mutations have been shown to contribute to the development of acute myelogenous leukemia, whereas mutations in TERT account for a proportion of individuals with an inherited bone marrow-failure syndrome that is prone to hematologic malignancies [29] [30] [31] . SNPs in the CLPTM1L-TERT region, including rs401681, are also associated with additional cancers, namely bladder and prostate cancer [22] [23] [24] . Notably, the C allele of rs401681 is associated with an increased risk of lung, prostate and bladder cancers, as well as with basal cell carcinoma [22] [23] [24] [25] , whereas the T allele is associated with increased risk of pancreatic cancer (shown in this study) and melanoma 25 . Lastly, a highly suggestive SNP in this region that did not meet genome-wide significance, rs4635969 (ranked 12th in the combined analysis, P = 1.05 × 10 −6 ), is located between CLPTM1L and TERT (r 2 = 0.26 in 3,650 study controls and r 2 = 0.36 in the HapMap CEU population).
It is notable that the estimated ORs for the variants meeting genome-wide significance on chromosomes 13q22, 1q32 and 5p15 were consistent when restricted to data from either the case-control studies or the cohort studies 6 . This similarity of estimated effect size between the two study designs was also observed for rs505922 in the ABO locus in our previous report 6 . This consistency of effect supports a role for loci at 13q22.1, 1q32.1, 5p15.33 and ABO in risk for pancreatic cancer, whereas the divergent results for SHH (reported earlier in ref. 6 ) on chromosome 7q36 indicate the need for further investigation of the potential influence of study sampling design on detection of risk regions using the GWAS strategy.
GWAS have emerged as a powerful, hypothesis-independent approach to identify common alleles that influence disease risk. Our results show that pancreatic cancer is similar to other complex diseases in that multiple common disease alleles with small effects influence disease risk. Our study has good power to detect common alleles with large effects (over 90% power to detect a per-allele relative risk of 1.4 or greater for an allele with 10% frequency at the α = 5 × 10 −7 level) but less power to detect smaller effect sizes. Thus, although it is unlikely that there are common alleles with large effects on most of sporadic pancreatic cancer risk, it is likely that additional susceptibility alleles with moderate to small effects exist. The list of susceptibility alleles should lengthen as further GWAS are performed for pancreatic cancer to catalog the variants with estimated risks below 1.3. Additional studies are needed to assess the clinical utility of risk stratification that combines genetic markers with epidemiologic risk factors already established for pancreatic cancer, namely adiposity, smoking, diabetes and family history.
Our combined analysis of 3,851 individuals with pancreatic cancer and 3,934 controls has yielded three new genomic regions associated with the risk of pancreatic cancer. Two of these regions harbor candidate genes, and the third locus, on chromosome 13q22.1, maps to a large nongenic region analogous to the 8q24 region; however, though the 8q24 region is associated with risk of multiple cancers, including prostate, breast, colorectal and bladder cancers, the locus on chromosome 13q22.1 appears to be specific for pancreatic cancer. The CPTM1L-TERT region on chromosome 5p15.33 has been implicated in a disease spectrum that also includes lung cancer, brain tumors, acute myelogenous leukemia, bone marrow failure syndromes and pulmonary fibrosis. The fine-mapping of signals in the three regions identified by our GWAS should guide selection of the optimal variants for functional studies investigating the biological mechanism underpinning pancreatic carcinogenesis. These results, in turn, should help to inform new preventive, diagnostic and/or therapeutic approaches designed to lessen the burden of this highly fatal disease.
MeThOdS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
contribution of the additional marker to the haplotype association with disease is warranted, conditional on current haplotypes, which is tested using a Mantel-Haenszel statistic.
Data analysis and management was performed with GLU (Genotyping Library and Utilities version 1.0), a suite of tools available as an open-source application for management, storage and analysis of GWAS data. Haplotype analysis was performed using R statistical software.
Estimate of recombination hot spots. SequenceLDhot 60 , an approximate marginal likelihood method 61 , was used to compute likelihood ratio statistics for a set of putative hot spots across a region. We sequentially analyzed subsets of 100 controls of European background (by pooling 5 controls from each study) and used Phasev2.1 62, 63 to infer the haplotypes as well as background recombination rates. To obtain robust results, the analysis was repeated with five nonoverlapping sets of 100 pooled controls.
Data access. The CGEMS data portal provides access to individual level data in 7,785 individuals to investigators from certified scientific institutions after approval of their submitted Data Access Request.
